FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149577037> ?p ?o ?g. }

• W2149577037 endingPage "778" @default.
• W2149577037 startingPage "778" @default.
• W2149577037 abstract "Although many patients with end-stage cancer are offered chemotherapy to improve quality of life (QOL), the association between chemotherapy and QOL amid progressive metastatic disease has not been well-studied. American Society for Clinical Oncology guidelines recommend palliative chemotherapy only for solid tumor patients with good performance status.To evaluate the association between chemotherapy use and QOL near death (QOD) as a function of patients' performance status.A multi-institutional, longitudinal cohort study of patients with end-stage cancer recruited between September 2002 and February 2008. Chemotherapy use (n = 158 [50.6%]) and Eastern Cooperative Oncology Group (ECOG) performance status were assessed at baseline (median = 3.8 months before death) and patients with progressive metastatic cancer (N = 312) following at least 1 chemotherapy regimen were followed prospectively until death at 6 outpatient oncology clinics in the United States.Patient QOD was determined using validated caregiver ratings of patients' physical and mental distress in their final week.Chemotherapy use was not associated with patient survival controlling for clinical setting and patients' performance status. Among patients with good (ECOG score = 1) baseline performance status, chemotherapy use compared with nonuse was associated with worse QOD (odds ratio [OR], 0.35; 95% CI, 0.17-0.75; P = .01). Baseline chemotherapy use was not associated with QOD among patients with moderate (ECOG score = 2) baseline performance status (OR, 1.06; 95% CI, 0.51-2.21; P = .87) or poor (ECOG score = 3) baseline performance status (OR, 1.34; 95% CI, 0.46-3.89; P = .59).Although palliative chemotherapy is used to improve QOL for patients with end-stage cancer, its use did not improve QOD for patients with moderate or poor performance status and worsened QOD for patients with good performance status. The QOD in patients with end-stage cancer is not improved, and can be harmed, by chemotherapy use near death, even in patients with good performance status." @default.
• W2149577037 created "2016-06-24" @default.
• W2149577037 creator A5010120171 @default.
• W2149577037 creator A5010388772 @default.
• W2149577037 creator A5027148722 @default.
• W2149577037 creator A5028299369 @default.
• W2149577037 creator A5045421873 @default.
• W2149577037 creator A5050353741 @default.
• W2149577037 creator A5051522382 @default.
• W2149577037 creator A5076060274 @default.
• W2149577037 creator A5080434143 @default.
• W2149577037 creator A5082554584 @default.
• W2149577037 creator A5085560257 @default.
• W2149577037 creator A5089202777 @default.
• W2149577037 date "2015-09-01" @default.
• W2149577037 modified "2023-10-17" @default.
• W2149577037 title "Chemotherapy Use, Performance Status, and Quality of Life at the End of Life" @default.
• W2149577037 cites W1966574632 @default.
• W2149577037 cites W1976029162 @default.
• W2149577037 cites W1980600844 @default.
• W2149577037 cites W1984595860 @default.
• W2149577037 cites W2000445173 @default.
• W2149577037 cites W2007060261 @default.
• W2149577037 cites W2023888294 @default.
• W2149577037 cites W2024501220 @default.
• W2149577037 cites W2025572003 @default.
• W2149577037 cites W2027463741 @default.
• W2149577037 cites W2051989799 @default.
• W2149577037 cites W2058656025 @default.
• W2149577037 cites W2070057564 @default.
• W2149577037 cites W2076668534 @default.
• W2149577037 cites W2096448257 @default.
• W2149577037 cites W2103084101 @default.
• W2149577037 cites W2109539147 @default.
• W2149577037 cites W2110882721 @default.
• W2149577037 cites W2119642155 @default.
• W2149577037 cites W2127152525 @default.
• W2149577037 cites W2128941584 @default.
• W2149577037 cites W2132245078 @default.
• W2149577037 cites W2133615628 @default.
• W2149577037 cites W2139377071 @default.
• W2149577037 cites W2139524347 @default.
• W2149577037 cites W2158366036 @default.
• W2149577037 cites W2169490447 @default.
• W2149577037 cites W2169678441 @default.
• W2149577037 doi "https://doi.org/10.1001/jamaoncol.2015.2378" @default.
• W2149577037 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4828728" @default.
• W2149577037 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26203912" @default.
• W2149577037 hasPublicationYear "2015" @default.
• W2149577037 type Work @default.
• W2149577037 sameAs 2149577037 @default.
• W2149577037 citedByCount "430" @default.
• W2149577037 countsByYear W21495770372015 @default.
• W2149577037 countsByYear W21495770372016 @default.
• W2149577037 countsByYear W21495770372017 @default.
• W2149577037 countsByYear W21495770372018 @default.
• W2149577037 countsByYear W21495770372019 @default.
• W2149577037 countsByYear W21495770372020 @default.
• W2149577037 countsByYear W21495770372021 @default.
• W2149577037 countsByYear W21495770372022 @default.
• W2149577037 countsByYear W21495770372023 @default.
• W2149577037 crossrefType "journal-article" @default.
• W2149577037 hasAuthorship W2149577037A5010120171 @default.
• W2149577037 hasAuthorship W2149577037A5010388772 @default.
• W2149577037 hasAuthorship W2149577037A5027148722 @default.
• W2149577037 hasAuthorship W2149577037A5028299369 @default.
• W2149577037 hasAuthorship W2149577037A5045421873 @default.
• W2149577037 hasAuthorship W2149577037A5050353741 @default.
• W2149577037 hasAuthorship W2149577037A5051522382 @default.
• W2149577037 hasAuthorship W2149577037A5076060274 @default.
• W2149577037 hasAuthorship W2149577037A5080434143 @default.
• W2149577037 hasAuthorship W2149577037A5082554584 @default.
• W2149577037 hasAuthorship W2149577037A5085560257 @default.
• W2149577037 hasAuthorship W2149577037A5089202777 @default.
• W2149577037 hasBestOaLocation W21495770372 @default.
• W2149577037 hasConcept C121608353 @default.
• W2149577037 hasConcept C126322002 @default.
• W2149577037 hasConcept C143998085 @default.
• W2149577037 hasConcept C159110408 @default.
• W2149577037 hasConcept C2776694085 @default.
• W2149577037 hasConcept C2776907518 @default.
• W2149577037 hasConcept C2778336483 @default.
• W2149577037 hasConcept C2779951463 @default.
• W2149577037 hasConcept C2781413609 @default.
• W2149577037 hasConcept C2994186709 @default.
• W2149577037 hasConcept C71924100 @default.
• W2149577037 hasConceptScore W2149577037C121608353 @default.
• W2149577037 hasConceptScore W2149577037C126322002 @default.
• W2149577037 hasConceptScore W2149577037C143998085 @default.
• W2149577037 hasConceptScore W2149577037C159110408 @default.
• W2149577037 hasConceptScore W2149577037C2776694085 @default.
• W2149577037 hasConceptScore W2149577037C2776907518 @default.
• W2149577037 hasConceptScore W2149577037C2778336483 @default.
• W2149577037 hasConceptScore W2149577037C2779951463 @default.
• W2149577037 hasConceptScore W2149577037C2781413609 @default.
• W2149577037 hasConceptScore W2149577037C2994186709 @default.
• W2149577037 hasConceptScore W2149577037C71924100 @default.
• W2149577037 hasIssue "6" @default.

• next